<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>生物制药小编 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-15T16:33:10+08:00</updated>
  <subtitle>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>《治疗用生物制品病毒污染风险控制要点》新书发布| 默克与药品监管部门合作，持续助力中国医药行业</title>
    <updated>2021-01-15T15:43:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/oi5yq1dDiDZl88MfVC4cJA</id>
    <link href="https://mp.weixin.qq.com/s/oi5yq1dDiDZl88MfVC4cJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体版PROTAC：AbTAC</title>
    <updated>2021-01-15T15:43:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/IQAxHim7emnXZgAdu8FTlw</id>
    <link href="https://mp.weixin.qq.com/s/IQAxHim7emnXZgAdu8FTlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>AXL:  新冠病毒进入人体细胞的新受体</title>
    <updated>2021-01-13T19:50:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/wWgJun3-HPqEH9ui5QkFGA</id>
    <link href="https://mp.weixin.qq.com/s/wWgJun3-HPqEH9ui5QkFGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖达雷妥尤单抗类似药正式获批临床</title>
    <updated>2021-01-13T19:50:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/vThwOxM0_taQfJbNzORcNQ</id>
    <link href="https://mp.weixin.qq.com/s/vThwOxM0_taQfJbNzORcNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>RNA干扰药物递送方法的简单梳理</title>
    <updated>2021-01-12T17:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/VZe6-gHexcHWj-RPMwGNcQ</id>
    <link href="https://mp.weixin.qq.com/s/VZe6-gHexcHWj-RPMwGNcQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>1985-2020年：1149款新药</title>
    <updated>2021-01-12T17:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/BzFatgUPRQxneqCIrA5qoA</id>
    <link href="https://mp.weixin.qq.com/s/BzFatgUPRQxneqCIrA5qoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>游方和尚专栏 | 创新药转化医学研究（三）：单抗药物临床前的安全性评价</title>
    <updated>2021-01-11T16:04:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/ZuTMvDo6gxgNkcKEI9Dauw</id>
    <link href="https://mp.weixin.qq.com/s/ZuTMvDo6gxgNkcKEI9Dauw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>线下研讨会(上海) | 抗体药物研发与工艺开发</title>
    <updated>2021-01-11T16:04:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/02RdK4WMr3qJEmFUaKA0Pg</id>
    <link href="https://mp.weixin.qq.com/s/02RdK4WMr3qJEmFUaKA0Pg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>老花眼：被忽视的临床需求，匹罗卡品在研药物三期临床成功，有望今年提交上市申请</title>
    <updated>2021-01-10T17:49:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/gVr68cBny1SMZ_WhS9OF2A</id>
    <link href="https://mp.weixin.qq.com/s/gVr68cBny1SMZ_WhS9OF2A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞博生物简析</title>
    <updated>2021-01-10T17:49:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/qaYYd5JDAgEL2nYCew2Xlg</id>
    <link href="https://mp.weixin.qq.com/s/qaYYd5JDAgEL2nYCew2Xlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体-肿瘤免疫调节剂偶联物—又一新贵</title>
    <updated>2021-01-09T20:29:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-09:/s/LYso92piTvlWditTRqpt3w</id>
    <link href="https://mp.weixin.qq.com/s/LYso92piTvlWditTRqpt3w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>EZH2抑制剂： 基于表观遗传的肿瘤免疫治疗药物，恒瑞布局</title>
    <updated>2021-01-08T15:52:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/c7a1zH5ggQ0y4DtHTOtGwA</id>
    <link href="https://mp.weixin.qq.com/s/c7a1zH5ggQ0y4DtHTOtGwA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体靶点对于ADC药代动力学的影响</title>
    <updated>2021-01-07T17:53:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/KH5AnItkWBeUg78-ymsZbg</id>
    <link href="https://mp.weixin.qq.com/s/KH5AnItkWBeUg78-ymsZbg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>游方和尚专栏 | 大分子生物分析概论（十一）： LBA测试中的稳定性问题及最佳实践</title>
    <updated>2021-01-06T15:32:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/ZOOKUITtGdAg_r2_UoNqxg</id>
    <link href="https://mp.weixin.qq.com/s/ZOOKUITtGdAg_r2_UoNqxg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>传统药企如何转型大分子新药研发</title>
    <updated>2021-01-06T15:32:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/6NUVVALrkspODfuzTUc0xg</id>
    <link href="https://mp.weixin.qq.com/s/6NUVVALrkspODfuzTUc0xg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年国内细胞治疗产品受理及获批情况及浅析</title>
    <updated>2021-01-06T07:43:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/-eaR6ScbgSEAUAd8TuAAsA</id>
    <link href="https://mp.weixin.qq.com/s/-eaR6ScbgSEAUAd8TuAAsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>免疫治疗奠基之路——抗体Fc工程化改造</title>
    <updated>2021-01-06T07:43:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/-N7V9zpYKTWhcRyjKJ2Jnw</id>
    <link href="https://mp.weixin.qq.com/s/-N7V9zpYKTWhcRyjKJ2Jnw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>